ASX:SPL Starpharma (SPL) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free SPL Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume351,391 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield9.30%Price TargetN/A Stock AnalysisStock Analysis Get Starpharma alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Starpharma Stock (ASX:SPL)Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" SPL Stock News HeadlinesApril 19, 2024 | americanbankingnews.comRobert Thomas Purchases 250,000 Shares of Starpharma Holdings Limited (ASX:SPL) StockJanuary 18, 2024 | ca.finance.yahoo.comStarpharma Holdings Limited (SPHRF)April 24, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...December 19, 2023 | finance.yahoo.comEven after rising 42% this past week, Starpharma Holdings (ASX:SPL) shareholders are still down 88% over the past three yearsDecember 18, 2023 | msn.comASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trialNovember 27, 2023 | msn.com“Market is going to be surprised” as Firebrick Pharma set to launch antiviral nasal spray, NasodineSeptember 13, 2023 | msn.comASX Health Stocks: Starpharma jumps 30pc after cancer drug helps enable ‘100 per cent’ control rateSeptember 13, 2023 | fool.com.auHere's why the Starpharma share price just exploded 50%!April 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.August 21, 2023 | sg.news.yahoo.comSPL ranks as 3rd-most popular football competition among Singaporeans: studyJuly 30, 2023 | fool.com.auWhy is this ASX All Ords share sinking 34% on Monday?July 13, 2023 | uk.finance.yahoo.comSPL.AX - Starpharma Holdings LimitedJuly 12, 2023 | forbes.comSPL IndustriesJune 13, 2023 | finance.yahoo.comInvestors in Starpharma Holdings (ASX:SPL) have unfortunately lost 68% over the last five yearsApril 10, 2023 | finance.yahoo.comWith 52% ownership of the shares, Starpharma Holdings Limited (ASX:SPL) is heavily dominated by institutional ownersMarch 1, 2023 | finance.yahoo.comStarpharma Holdings First Half 2023 Earnings: AU$0.02 loss per share (vs AU$0.021 loss in 1H 2022)January 2, 2023 | finance.yahoo.comStarpharma Holdings (ASX:SPL) shareholders have endured a 60% loss from investing in the stock five years agoNovember 29, 2022 | reuters.comStarpharma Holdings LtdNovember 22, 2022 | finance.yahoo.comShareholders May Be More Conservative With Starpharma Holdings Limited's (ASX:SPL) CEO Compensation For NowOctober 18, 2022 | investing.comSPL Industries Ltd (SPND)October 17, 2022 | finance.yahoo.comStarpharma Holdings Limited (ASX:SPL) is a favorite amongst institutional investors who own 53%September 3, 2022 | fool.com.auWhy the Starpharma share price rocketed 14% higher todayAugust 29, 2022 | fool.com.auWhy the Starpharma Holdings Limited share price rocketed 10% higher todayJune 29, 2022 | fool.com.auStarphama share price lunges 5% on product relaunchJune 23, 2022 | finance.yahoo.comStarpharma Holdings (ASX:SPL) shareholders have endured a 56% loss from investing in the stock a year agoMay 26, 2022 | investing.comStarpharma Holdings Ltd (SPHRY)May 12, 2022 | nz.finance.yahoo.comTrellix Accelerates Growth in First 100 DaysSee More Headlines Receive SPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:SPL CUSIPN/A CIKN/A Webwww.starpharma.com Phone+61-3-85322700FaxN/AEmployees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,390,000.00 Net Margins-79.79% Pretax MarginN/A Return on Equity-22.25% Return on Assets-10.50% Debt Debt-to-Equity Ratio9.08 Current Ratio5.60 Quick Ratio5.65 Sales & Book Value Annual Sales$10.52 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.42 Book ValueA$0.08 per share Price / BookN/AMiscellaneous Outstanding Shares412,040,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.77 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Justin CahillCFO & Company SecretaryMs. Cheryl Maley B.Sc. (Age 55)M.B.A., CEO, MD & Director Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersRobert ThomasBought 100,000 shares on 4/15/2024Total: $13,000.00 ($0.13/share)Russell BasserBought 71,428 shares on 4/12/2024Total: $9,999.92 ($0.14/share)Robert ThomasBought 250,000 shares on 4/10/2024Total: $43,500.00 ($0.17/share)Jacinth (Jackie) FairleySold 667,441 sharesTotal: $90,104.54 ($0.14/share)Jacinth (Jackie) FairleySold 514,918 sharesTotal: $69,513.93 ($0.14/share) SPL Stock Analysis - Frequently Asked Questions How were Starpharma's earnings last quarter? Starpharma Holdings Limited (ASX:SPL) released its quarterly earnings data on Wednesday, February, 27th. The company reported ($0.02) EPS for the quarter. Starpharma had a negative net margin of 79.79% and a negative trailing twelve-month return on equity of 22.25%. What other stocks do shareholders of Starpharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Starpharma investors own include Allena Pharmaceuticals (ALNA), Aurora Cannabis (ACBFF), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Amira Nature Foods (ANFI), Apellis Pharmaceuticals (APLS) and This page (ASX:SPL) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Starpharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
